<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03260920</url>
  </required_header>
  <id_info>
    <org_study_id>FTDOXY17EF</org_study_id>
    <nct_id>NCT03260920</nct_id>
  </id_info>
  <brief_title>Intranasal Oxytocin for Frontotemporal Dementia</brief_title>
  <acronym>FOXY</acronym>
  <official_title>A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weston Brain Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berry Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and effects on behaviour of
      Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive
      saline substance that contains no medication) in participants with frontotemporal
      dementia/Pick's disease. This study will take place in approximately 15 centres across Canada
      and the United States. Approximately 112 patients in total will be enrolled in this study. In
      the first phase we will examine which of three different dosing schedules of oxytocin may be
      more effective. In the second phase of the study, patients entering the study will be
      randomized to the oxytocin dosing schedule that appeared most effective in the first phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A Proof-of-Concept Double Blind Randomized Controlled, Cross-Over Adaptive Design Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Neuropsychiatric Inventory (NPI) apathy/indifference domain score</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Pilot data from our two prior studies of oxytocin in FTD have driven the selection of the NPI as the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in emotional facial expression recognition performance</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Revised Self-Monitoring Scale score</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Clinicians Global Impression of Change (apathy) scores</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon</intervention_name>
    <description>Intranasal Oxytocin</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Medium Dose</arm_group_label>
    <other_name>Intranasal Oxytocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of probable FTD (behavioural variant FTD, FTD-semantic subtype or
             FTD-Progressive Nonfluent Aphasia) with supportive brain imaging (centrally rated
             frontotemporal atrophy score of 2 or greater on brain MRI or CT) or known FTD causing
             genetic mutation.68

          -  Current symptoms of social apathy/indifference as measured by NPI apathy/indifference
             severity subscale score &gt;= 2 indicating the presence of moderate to marked levels of
             apathy/indifference.

          -  Study partner who consents to study participation and who cares for/visits the patient
             daily for at least 3 hours/day and who can administer all trial medications.

          -  FTLD-CDR score 0-2.

          -  MMSE &gt;10.

          -  Stable baseline medications related to cognition or behaviour for &gt;=30 days such as
             acetylcholinesterase inhibitors, memantine, anti-depressants, antipsychotic agents,
             other mood stabilizers, benzodiazepines.

          -  Written informed consent must be obtained and documented (from the patient or, where
             jurisdictions allow it, from their substitute decision maker).

        Exclusion Criteria:

          -  History of stroke, other neurologic or psychiatric disorder other than FTD that is
             considered to better account for behavioural symptoms.

          -  History of a myocardial infarction within the last two years or congestive heart
             failure.

          -  Current uncontrolled hypertension

          -  Current bradycardia (rate &lt; 50 beats per minute/bpm) or tachycardia (rate &gt; 100 bpm)

          -  Current hyponatremia (Na &lt;135 mEq/L)

          -  Current use of topical prostaglandin medications applied to the cervix.

          -  Females who are pregnant or breastfeeding, or planning to conceive within the study
             period.

          -  Use of any investigational or experimental drug or device within the last 60 days
             prior to screening or within 5 half-lives of the experimental drug, whichever is
             longer.

          -  Participant has speech difficulties that in the opinion of the investigator would be
             incompatible with neuropsychology and safety assessments

          -  History of cancer except:

               -  If considered to be cured

               -  If not being actively treated with anti-cancer therapy or radiotherapy and, in
                  the opinion of the investigator, not likely to require treatment in the ensuing 5
                  years

               -  For prostate cancer or basal cell carcinoma, no significant progression over the
                  previous 2 years

          -  Any clinically significant hematological, endocrine, cardiovascular, renal, hepatic,
             gastrointestinal or neurological disease. If the condition has been stable for at
             least the past year and is judged by the investigator not to interfere with the
             patient's participation in the study, the patient may be included.

          -  For the CSF sub-study, current use of anticoagulant medications (warfarin,
             rivaroxaban, etc.).

          -  Plan for FTD patient to be placed into long-term care or plan for hospital admission
             for any kind of treatment within study period or if caregiver plans for
             holidays/respite care &gt; 3 days during study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Chavez</last_name>
      <phone>310-478-3711</phone>
      <phone_ext>48176</phone_ext>
      <email>dianachavez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Mario Mendez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Koestler</last_name>
      <phone>415-476-0661</phone>
      <email>mary.koestler@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Boxer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Lawrence, MS</last_name>
      <phone>410-550-9020</phone>
      <email>swoody1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Chiadi U Onyike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Silverman</last_name>
      <phone>212-305-6284</phone>
      <email>hs2971@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Huey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Caso</last_name>
      <phone>206-221-9038</phone>
      <email>cdcaso@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Kimiko Domoto-Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloise Nicklin</last_name>
      <phone>(604) 822-0324</phone>
      <email>eloise.nicklin@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Robin Hsiung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Jesso, BA</last_name>
      <phone>519-646-6000</phone>
      <email>cognitiveneurology@sjhc.london.on.ca</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Finger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Sharp</last_name>
      <phone>(416) 480-6100</phone>
      <phone_ext>1620</phone_ext>
      <email>kathryn.sharp@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Mario Masellis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Salvo</last_name>
      <phone>(416) 603-2581</phone>
      <email>cristina.salvo@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Carmela Tartaglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucile Rapin</last_name>
      <phone>(514) 398-5750</phone>
      <email>lucile.rapin@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Simon Ducharme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Quebec</city>
        <zip>G1J1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonie Proulx</last_name>
      <phone>418-649-0252</phone>
      <email>leonie.proulx@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Robert LaForce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>frontotemporal dementia</keyword>
  <keyword>apathy</keyword>
  <keyword>empathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

